Compass Therapeutics, Inc. — Director's Dealing 2020

Sep 15, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Compass Therapeutics, Inc. (NONE)
CIK: 0001738021
Period of Report: 2020-09-10

Reporting Person: Kaplan Brett (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-09-10	Stock Option (Right to Buy)	$5.00	A	60000	Acquired	2030-09-10	Common Stock (60000)	Direct

Footnotes

F1: This option shall vest in substantially equal monthly installments over four years.